Yuji Kaneoka

5.5k citations
167 papers · 3.3k indexed · 1 hit paper · h-index 29

Yuji Kaneoka

149 papers receiving 3.2k citations

Hit Papers

Adjuvant chemotherapy of S-1 versus gemcitabine for resec...7422016202620192022200400600

Peers

Yuji Kaneoka
Comparison fields: 5 of 104
  • Hepatology 1.1k
  • Oncology 1.6k
  • Cancer Research 574
  • Surgery 1.5k
  • Epidemiology 1.1k
Replace Atsuyuki Maeda with:
Atsuyuki Maeda Japan
Ray‐Hwang Yuan Taiwan
Shinji Togo Japan
Marcus Bahra Germany
Masaji Hashimoto Japan
Srinevas K. Reddy United States
Yanming Zhou China
Andrea Ruzzenente Italy
Akira Chikamoto Japan
Parissa Tabrizian United States
Yuji Kaneoka relative to Atsuyuki Maeda Japan Atsuyuki Maeda's profile →
Citations per field
00.5×1.5×1.9×
Atsuyuki Maeda · 1×
Citations per year

Countries citing papers authored by Yuji Kaneoka

Since Specialization
Citations

This map shows the geographic impact of Yuji Kaneoka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuji Kaneoka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuji Kaneoka more than expected).

Fields of papers citing papers by Yuji Kaneoka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuji Kaneoka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuji Kaneoka. The network helps show where Yuji Kaneoka may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yuji Kaneoka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yuji Kaneoka Line = papers co-authored together Yuji Kaneoka links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20222
2 20216
3 20216
4 20197
5 20164
6 20121
7 20121
8 20121
9 20121
10 20093
11 20080
12 20082
13 20083
14 20032
15 20022
16 200210
17 20012
18 20019
19 20011
20 200110

About Yuji Kaneoka

Yuji Kaneoka is a scholar working on Hepatology, Gastroenterology and Surgery, having authored 167 papers that have together received 3.3k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (39 papers), Pancreatic and Hepatic Oncology Research (33 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (33 papers), Liver Disease Diagnosis and Treatment (23 papers), Gallbladder and Bile Duct Disorders (23 papers), Gastrointestinal disorders and treatments (17 papers), Gastric Cancer Management and Outcomes (17 papers) and Gastrointestinal Tumor Research and Treatment (16 papers). The work is most often cited by research in Hepatology (1.1k citations), Oncology (1.6k citations) and Cancer Research (574 citations). Yuji Kaneoka has collaborated with scholars based in Japan, United States and France. Frequent co-authors include Atsuyuki Maeda, Masatoshi Isogai, Takashi Kumada, Hidenori Toyoda, Akihiro Yamaguchi, Toshifumi Tada, Yasuhiro Sone, Yuichi Takayama, Yasuyuki Fukami and Satoshi Hirano. Their work appears in journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026